Shopping Cart

Remove All

Your shopping cart is currently empty

FNDC1 Protein, Human, Recombinant (His)

Resource Download

COA

FNDC1 Protein, Human, Recombinant (His)

Catalog No. TMPK-00994

Fibronectin type III domain‑containing protein 1 (FNDC1) is a protein that contains a major component of the structural domain of fibronectin.FNDC1 was highly upregulated and acted as an oncogene in BC. Therefore, targeting FNDC1 may be a potential strategy for the treatment of BC.

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Pack Size	Price	Availability
100 μg	$418	7-10 days
500 μg	$1,670	7-10 days
1 mg	$2,800	7-10 days

Bulk & Custom

Add to Cart

Questions

Biological Description

Description	Fibronectin type III domain‑containing protein 1 (FNDC1) is a protein that contains a major component of the structural domain of fibronectin.FNDC1 was highly upregulated and acted as an oncogene in BC. Therefore, targeting FNDC1 may be a potential strategy for the treatment of BC.
Species	Human
Expression System	E. coli
Tag	N-His
Accession Number	Q4ZHG4-1
Synonyms	FNDC2,MEL4B3,KIAA1866
Construction	Ala33-Thr457
Protein Purity	> 95% as determined by Tris-Bis PAGE; > 95% as determined by HPLC
Molecular Weight	48.68 kDa (predicted). The protein migrates to 50-55 kDa based on Tris-Bis PAGE result.
Endotoxin	< 1 EU/μg by the LAL method.
Formulation	Supplied as 0.22 μm filtered solution in 20 mM PB, 500 mM NaCl, 10% Glycerol.
Stability & Storage	It is recommended to store the product under sterile conditions at -70°C or lower. Samples are stable for up to 12 months at -80°C. Please avoid multiple freeze-thaw cycles and store products in aliquots.
Shipping	In general, Lyophilized powders are shipping with blue ice. Solutions are shipping with dry ice.
Research Background	Fibronectin type III domain‑containing protein 1 (FNDC1) is a protein that contains a major component of the structural domain of fibronectin.FNDC1 was highly upregulated and acted as an oncogene in BC. Therefore, targeting FNDC1 may be a potential strategy for the treatment of BC.